ClinicalTrials.gg
RecruitingNCT06503523Updated Nov 9, 2026

The Effects of Performing a Motor Imagery Task on Cortical Excitability During Acute Experimental Muscle Pain and Acute Itch

An interventional study of Hypertonic Saline and Histamine in Itch and Pain, sponsored by Aalborg University. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Aalborg University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Pruritus by Aalborg University — 4 open to participants now, 6 under way, none of them phase 3. Pruritus · Aalborg University.

Planned enrollment
3rd of 25
30 · median 25
Started
2024
with 2 others
No phase
25 of 25
4 open now
Registered
20th of 25
by date

Among the 25 studies in Pruritus by Aalborg University, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 25 with no phase, and was the 20th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

4 of the 25 studies in Pruritus by Aalborg University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pruritus by Aalborg University, or all of them as a file.
02

Study summary

The aim of this project is to determine the effects of performing a motor imagery task on cortical excitability during acute experimental muscle pain (induced by hypertonic saline), acute histaminergic itch (induced by histamine), and non-histaminergic itch stimulation (triggered by Cowhage). We hypothesize that motor imagery will counteract the alterations in cortical excitability observed during experimental muscle pain and both itch models.

Read the detailed description

Itch and pain share many similarities and dissimilarities in terms of the mechanisms and molecules involved. Many studies have been conducted to explain all the neurophysiological aspects involved in the pain process, and cortical adaptations have been provoked in healthy individuals using experimental pain models. Unfortunately, all these aspects still need to be clarified regarding itch. Has been previously demonstrated that motor imagery can counteracted the pain-induced decrease in corticospinal excitability observed during acute pain, and it has also been proposed as a potential intervention for individuals with pain to restore maladaptive neuroplasticity. However, whether motor imagery can similarly counteract the itch-induced cortical changes remains unclear. Therefore, the aim of this project is to investigate whether motor imagery would counteract the reduction in cortical excitability during acute itch, similar to the effects observed in the context of acute pain.

03

Conditions studied

  • Itch
  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men and women
  • 18-60 years
  • Speak and understand English

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other addictive drugs
  • Previous or current history of neurological (e.g. neuropathy), immunological (e.g. asthma, immune deficiencies, arthritis), musculoskeletal (e.g. muscular pain in the upper extremities,), cardiac disorder (e.g., heart stroke), or psychiatric diagnoses (e.g. depression) that may affect the results
  • Current use of medications that may affect the trial, such as antihistamines, antipsychotics, and painkillers, as well as systemic or topical
  • Skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis)
  • Moles, scars, or tattoos in the area to be treated or tested.
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Acute or chronic pain
  • Unable to pass the "Transcranial Magnetic Stimulation Adult Safety Screen" (subproject 1 and 2)
  • to transcranial magnetic stimulation (TMS) application (history of epilepsy, metal implants in head or jaw, etc.)
  • Presence of implanted hearing aids or metal implants on the face, including permanent makeup or tattoos
  • Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
  • Lack of ability to cooperate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental:Healthy volunteers

    Other: Hypertonic Saline · Other: Histamine · Other: Cowhage · Device: Transcranial magnetic stimulation (TMS)

Interventions

  • OtherHypertonic Saline

    A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and the volume of the bolus will be 0.1 mL

  • OtherHistamine

    A small drop of histamine dihydrochloride will be applied to a previously determined area on the volar forearm, followed by a prick through the drop

  • OtherCowhage

    This insertion is conducted by forceps using a stereomicroscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.

  • DeviceTranscranial magnetic stimulation (TMS)

    Transcranial magnetic stimulation (TMS) will be used to evoke motor-evoked potentials (MEPs) in the muscle of interest and cortical responses (TMSevoked potentials - TEPs) in the motor cortex with a figure-eight-shaped cone coil.

06

What researchers measure

Primary outcomes

  1. Numeric rating scales (NRS)

    NRS are essentially VAS but have tick marks spaced every centimeter so as to create 11-point scale (from 0 to 10). Subject can use these tick marks as a guide when they mark their severity on the scale.

    Time frame: 1 minute after every itch/pain induction

  2. Measuring cortical excitability (TEPs)

    Transcranial magnetic stimulation (TMS) with a figure-eight-shaped cone coil will be used to evoke cortical responses in the motor cortex. The resulting TMS-evoked potentials (TEPs) will be collected using an electroencephalogram (EEG). This assessment will last for 7 minutes before inducing itch or pain.

    Time frame: Baseline

  3. Measuring cortical excitability (TEPs)

    Transcranial magnetic stimulation (TMS) with a figure-eight-shaped cone coil will be used to evoke cortical responses in the motor cortex. The resulting TMS-evoked potentials (TEPs) will be collected using an electroencephalogram (EEG). This assessment will last for 7 minutes during itch or pain. The pain or itch sensation will last 10 minutes.

    Time frame: During Itch/pain stimulation for 10 minutes

  4. Measuring cortical excitability (TEPs)

    Transcranial magnetic stimulation (TMS) with a figure-eight-shaped cone coil will be used to evoke cortical responses in the motor cortex. The resulting TMS-evoked potentials (TEPs) will be collected using an electroencephalogram (EEG). This assessment will last for 7 minutes during motor imagery task.

    Time frame: During motor imagery task for 7 minutes

  5. Measuring cortical excitability (TEPs)

    Transcranial magnetic stimulation (TMS) with a figure-eight-shaped cone coil will be used to evoke cortical responses in the motor cortex. The resulting TMS-evoked potentials (TEPs) will be collected using an electroencephalogram (EEG). Similar to the baseline, this assessment will last for 7 minutes after itch or pain.

    Time frame: Post induction of itch or pain

Secondary outcomes

  1. Pain Catastrophizing Scale (PCS).

    The PCS assesses negative and exaggerated coping concerning anticipated or experienced painful stimuli. Thirteen items have to be answered on a 5-point Likert-type scale.

    Time frame: Baseline

  2. Itch Catastrophizing Scale (ICS).

    The ICS assesses negative and exaggerated coping concerning anticipated or experienced itchy stimuli. Thirteen items have to be answered on a 5-point Likert-type scale.

    Time frame: Baseline

  3. Reinforcement Sensitivity Theory - Personality Questionnaire (RST-PQ).

    The RST-PQ contains the following subscales: the Fight-Flight-Freeze System (FFFS, 10 items), which represents a defensive factor related to active avoidance of adverse stimuli; the Behavioral Inhibition System (BIS, 23 items), which represents a defensive factor related to anxiety and passive avoidance of adverse stimuli; and the Behavioral Approach System (BAS, 32 items), which reflects reward interest, goal-drive persistence, reward reactivity, and impulsivity. In total, 65 items have to be answered on a 4-point Likert-type scale

    Time frame: Baseline

  4. The Pittsburg Sleep Quality Index (PSQI)

    The PSQI consists of 19 items generating seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The seven component scores can be summarized in a global score ranging from zero to 21 with higher scores reflecting a worse overall quality of sleep

    Time frame: Baseline

  5. Depression, Anxiety, Stress Scale (DASS-21)

    The questionnaire measures the magnitude of depression, anxiety, and stress. Each of these three subscales consists of 7 questions answered using a 0-3 Likert scale, with 0 meaning "it did not apply to me", and 3 meaning "it applied to me very much".

    Time frame: Baseline

  6. Learned Helplessness Scale (LHS)

    The questionnaire consists of 20 items, and the participant's response to each item is rated on a 4-point Likert scale ranging from strongly agree (1) to strongly disagree (4).

    Time frame: Baseline

  7. Positive And Negative Affect Schedule (PANAS)

    PANAS measures positive and negative affect dimensions. Twenty words are associated with the subject's current feelings and have to be rated on a 5-points Likert-type scale.

    Time frame: Baseline

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 14 months.

Of 85 non-industry interventional studies with no phase under Pruritus, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 101 studies reached it within 7 months; a quarter within 3 and three quarters within 13.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Jul 16, 2024
StartActual
Oct 1, 2024
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date, date precision and oversight details
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 3 other changes: verification date, date precision and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06503523
Lead sponsor
Aalborg University
Responsible party
Silvia Lo Vecchio (Associate Professor, Aalborg University) — Principal investigator
First posted
Jul 16, 2024
Start date
Oct 1, 2024
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026 (estimated)
Last update
Nov 9, 2026

Study contacts

Silvia Lo Vecchio
Contact
slv@hst.aau.dk
21397785

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion